1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Acquired (Autoimmune) Hemolytic Anemia - Pipeline Review, H1 2015

Acquired (Autoimmune) Hemolytic Anemia - Pipeline Review, H1 2015

  • February 2015
  • -
  • Global Markets Direct
  • -
  • 57 pages

Acquired (Autoimmune) Hemolytic Anemia - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Acquired (Autoimmune) Hemolytic Anemia - Pipeline Review, H1 2015’, provides an overview of the Acquired (Autoimmune) Hemolytic Anemia’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Acquired (Autoimmune) Hemolytic Anemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acquired (Autoimmune) Hemolytic Anemia and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Acquired (Autoimmune) Hemolytic Anemia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Acquired (Autoimmune) Hemolytic Anemia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Acquired (Autoimmune) Hemolytic Anemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Acquired (Autoimmune) Hemolytic Anemia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Acquired (Autoimmune) Hemolytic Anemia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Acquired (Autoimmune) Hemolytic Anemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Acquired (Autoimmune) Hemolytic Anemia - Pipeline Review, H1 2015
Table of Contents
Introduction 5
Global Markets Direct Report Coverage 5
Acquired (Autoimmune) Hemolytic Anemia Overview 6
Therapeutics Development 7
Pipeline Products for Acquired (Autoimmune) Hemolytic Anemia - Overview 7
Pipeline Products for Acquired (Autoimmune) Hemolytic Anemia - Comparative Analysis 8
Acquired (Autoimmune) Hemolytic Anemia - Therapeutics under Development by Companies 9
Acquired (Autoimmune) Hemolytic Anemia - Pipeline Products Glance 10
Clinical Stage Products 10
Early Stage Products 11
Unknown Stage Products 12
Acquired (Autoimmune) Hemolytic Anemia - Products under Development by Companies 13
Acquired (Autoimmune) Hemolytic Anemia - Companies Involved in Therapeutics Development 14
Agios Pharmaceuticals, Inc. 14
Alexion Pharmaceuticals, Inc. 15
Hansa Medical AB 16
Shire Plc 17
Acquired (Autoimmune) Hemolytic Anemia - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
AG-348 - Drug Profile 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
C1 esterase inhibitor (human) - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
eculizumab - Drug Profile 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
Endoglycosidase of Streptococcus pyogenes - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
TNT-003 - Drug Profile 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
TNT-009 - Drug Profile 35
Product Description 35
Mechanism of Action 35
RandD Progress 35
Acquired (Autoimmune) Hemolytic Anemia - Recent Pipeline Updates 36
Acquired (Autoimmune) Hemolytic Anemia - Dormant Projects 46
Acquired (Autoimmune) Hemolytic Anemia - Product Development Milestones 47
Featured News and Press Releases 47
Dec 08, 2014: Agios Reports Positive Phase 1 Data in Healthy Volunteers for AG-348, a First-in-Class Investigational Medicine That Targets the Underlying Cause of Pyruvate Kinase (PK) Deficiency 47
Nov 06, 2014: Agios Pharmaceuticals To Present Phase 1 Data On AG-348 At The 2014 American Society Of Hematology Annual Meeting 48
Oct 06, 2014: Agios Pharmaceuticals to Provides Update on AG-348 Webcast RandD Day on October 15, 2014 49
Jun 09, 2014: Agios Pharmaceuticals Initiates Multiple Ascending Dose Trial in Healthy Volunteers of AG-348 for the Potential Treatment of PK Deficiency, a Rare, Hemolytic Anemia 50
Apr 17, 2014: Agios Initiates Phase 1 Study of AG-348, a First-in-class PKR Activator, for Pyruvate Kinase Deficiency 50
Apr 14, 2014: True North Therapeutics Publishes Study in Blood Demonstrating Ex Vivo Efficacy of a C1s Antibody in Cold Agglutinin Disease Patient Samples 51
Dec 16, 2013: Soliris Concentrated Solution for Intravenous Infusion by Alexion: Recall - Visible Particles 52
Dec 13, 2013: Alexion Provides Update on Previously Communicated November 2013 Voluntary Nationwide Recall of Two Lots of Soliris Concentrated Solution for Intravenous Infusion 52
Dec 09, 2013: True North Therapeutics Presents Preclinical Results Showing Potential of TNT009 to Treat Complement-Mediated Rare Diseases 53
Jun 11, 2011: Alexion Presents Additional Data At EHA Congress Describing Long-Term Efficacy And Survival Data With Sustained Soliris Therapy 54
Appendix 56
Methodology 56
Coverage 56
Secondary Research 56
Primary Research 56
Expert Panel Validation 56
Contact Us 56
Disclaimer 57

List of Tables

Number of Products under Development for Acquired (Autoimmune) Hemolytic Anemia, H1 2015 7
Number of Products under Development for Acquired (Autoimmune) Hemolytic Anemia - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Comparative Analysis by Clinical Stage Development, H1 2015 10
Comparative Analysis by Early Stage Development, H1 2015 11
Comparative Analysis by Unknown Stage Development, H1 2015 12
Products under Development by Companies, H1 2015 13
Acquired (Autoimmune) Hemolytic Anemia - Pipeline by Agios Pharmaceuticals, Inc., H1 2015 14
Acquired (Autoimmune) Hemolytic Anemia - Pipeline by Alexion Pharmaceuticals, Inc., H1 2015 15
Acquired (Autoimmune) Hemolytic Anemia - Pipeline by Hansa Medical AB, H1 2015 16
Acquired (Autoimmune) Hemolytic Anemia - Pipeline by Shire Plc, H1 2015 17
Assessment by Monotherapy Products, H1 2015 18
Number of Products by Stage and Target, H1 2015 20
Number of Products by Stage and Mechanism of Action, H1 2015 22
Number of Products by Stage and Route of Administration, H1 2015 24
Number of Products by Stage and Molecule Type, H1 2015 26
Acquired (Autoimmune) Hemolytic Anemia Therapeutics - Recent Pipeline Updates, H1 2015 36
Acquired (Autoimmune) Hemolytic Anemia - Dormant Projects, H1 2015 46

List of Figures

Number of Products under Development for Acquired (Autoimmune) Hemolytic Anemia, H1 2015 7
Number of Products under Development for Acquired (Autoimmune) Hemolytic Anemia - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Comparative Analysis by Clinical Stage Development, H1 2015 10
Comparative Analysis by Early Stage Products, H1 2015 11
Assessment by Monotherapy Products, H1 2015 18
Number of Products by Top 10 Targets, H1 2015 19
Number of Products by Stage and Top 10 Targets, H1 2015 20
Number of Products by Top 10 Mechanism of Actions, H1 2015 21
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 22
Number of Products by Top 10 Routes of Administration, H1 2015 23
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 24
Number of Products by Top 10 Molecule Types, H1 2015 25
Number of Products by Stage and Top 10 Molecule Types, H1 2015 26

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Drugs and Diagnostics for Hematological Disorders: Global Markets

Drugs and Diagnostics for Hematological Disorders: Global Markets

  • $ 6650
  • Industry report
  • September 2016
  • by BCC Research

Use this report to: - Receive detailed information regarding screening, testing and treatment options for hematological disorders and blood cancer. - Learn about the types of diagnostic and treatment ...

Sepsis Diagnostics Market by Technology, Product, Method, Usability, Pathogen - Global Forecast to 2021

Sepsis Diagnostics Market by Technology, Product, Method, Usability, Pathogen - Global Forecast to 2021

  • $ 5650
  • Industry report
  • September 2016
  • by MarketsandMarkets

The sepsis diagnostics market is expected to reach USD 564.1 million by 2021, at a CAGR of 8.8% from 2016 to 2021. The sepsis diagnostics market is primarily driven by the rising prevalence of sepsis in ...

Hemophilia A and B Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Increasing Treatment-Receiving Pool, Launch of Long-Acting Replacement Therapies and Non-factor Therapy

Hemophilia A and B Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Increasing Treatment-Receiving Pool, Launch of Long-Acting Replacement Therapies and Non-factor Therapy

  • $ 4995
  • Industry report
  • November 2016
  • by GBI Research

Hemophilia A and B Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Increasing Treatment-Receiving Pool, Launch of Long-Acting Replacement Therapies and Non-factor Therapy Summary Hemophilia ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.